Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Escape from Host-Antitumor Immunity

Volume 8, Issue 2-3, 1997, pp. 111-142
DOI: 10.1615/CritRevOncog.v8.i2-3.10
Get accessGet access

ABSTRACT

Cancer cells may express proteins recognizable by the individual's immune system as foreign because they are either tumor-specific or not expressed at high levels in normal tissues to which the host is tolerant. There is now much evidence that tumors can be immunogenic, that is, that they frequently express antigens in a form recognizable by the host immune system. This has been shown not only in experimental animals but also for spontaneously occurring human tumors. Tumors therefore may progress by evolving variants that can evade immune responses or by developing other strategies to "escape" the immune response. The purpose of this review is to consider the current status of knowledge concerning these different tumor escape strategies.

CITED BY
  1. Cabrera C.M., Jimenez P., Concha A., Garrido F., Ruiz-Cabello F., Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation, Tissue Antigens, 63, 5, 2004. Crossref

  2. Spisek Radek, Dhodapkar Madhav V., Immunoprevention of Cancer, Hematology/Oncology Clinics of North America, 20, 3, 2006. Crossref

  3. Cabrera Carmen M., López-Nevot Miguel-Ángel, Jiménez Pilar, Garrido Federico, Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors, International Journal of Cancer, 113, 4, 2005. Crossref

  4. Halapil Eva, Jeddi-Tehrani Mahmood, �sterborg Anders, Mellstedt H�kan, T cell receptor usage in malignant diseases, Springer Seminars in Immunopathology, 21, 1, 1999. Crossref

  5. Matzku Siegfried, Z??ller Margot, Specific Immunotherapy of Cancer in Elderly Patients, Drugs & Aging, 18, 9, 2001. Crossref

  6. De Vita Ferdinando, Orditura Michele, Galizia Gennaro, Romano Ciro, Infusino Stefania, Auriemma Annunziata, Lieto Eva, Catalano Giuseppe, Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies, Cancer, 86, 10, 1999. Crossref

  7. Cabrera C.M., Jiménez P., Cabrera T., Esparza C., Ruiz-Cabello F., Garrido F., Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2 -microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors, Tissue Antigens, 61, 3, 2003. Crossref

  8. C�fa� Daniel, Morrison Briggs W., Sckell Axel, Favre Luc, Balli Marietta, Leunig Michael, Gimmi Claude D., Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer, International Journal of Cancer, 83, 3, 1999. Crossref

  9. Cochlovius Bj�rn, Linnebacher Michael, Zewe-Welschof Monika, Z�ller Margot, Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell responsein vitro andin vivo, International Journal of Cancer, 83, 4, 1999. Crossref

  10. Flechner, Stuart M., Finke, James H., Fairchild, Robert L., Basic Principles of Immunology in Urology, in Campbell-Walsh Urology, 2012. Crossref

  11. Straten Per thor, Guldberg Per, Schrama David, Andersen Mads Hald, Moerch Ulrik, Seremet Tina, Siedel Claudia, Reisfeld Ralph A., Becker Jürgen C., In situ cytokine therapy: redistribution of clonally expanded T cells, European Journal of Immunology, 31, 1, 2001. Crossref

  12. Méndez Rosa, Ruiz-Cabello Francisco, Rodríguez Teresa, Del Campo Ana, Paschen Annette, Schadendorf Dirk, Garrido Federico, Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy, Cancer Immunology, Immunotherapy, 56, 1, 2007. Crossref

  13. Garg Neeraj Kumar, Dwivedi Priya, Prabha Punit, Tyagi Rajeev K., RNA pulsed dendritic cells: An approach for cancer immunotherapy, Vaccine, 31, 8, 2013. Crossref

  14. Kortylewski Marcin, Yu Hua, Stat3 as a Potential Target for Cancer Immunotherapy, Journal of Immunotherapy, 30, 2, 2007. Crossref

  15. Deepak Praveen, Kumar Sanjay, Kishore Dhiraj, Acharya Arbind, IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma, International Immunology, 22, 1, 2010. Crossref

  16. Lineweaver Charles H., Davies Paul C. W., Vincent Mark D., Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model, BioEssays, 36, 9, 2014. Crossref

  17. Wondimu Assefa, Zhang Tianqian, Kieber-Emmons Thomas, Gimotty Phyllis, Sproesser Katrin, Somasundaram Rajasekharan, Ferrone Soldano, Tsao Chun-Yen, Herlyn Dorothee, Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice, Cancer Immunology, Immunotherapy, 57, 7, 2008. Crossref

  18. Demirtzoglou F.J., Papadopoulos S., Zografos G., Cytolytic and Cytotoxic Activity of a Human Natural Killer Cell Line Genetically Modified to Specifically Recognize HER-2/neu Overexpressing Tumor Cells, Immunopharmacology and Immunotoxicology, 28, 4, 2006. Crossref

  19. Bruserud Øystein, Ulvestad Elling, Acute Myelogenous Leukemia Blasts as Accessory Cells during in Vitro T Lymphocyte Activation, Cellular Immunology, 206, 1, 2000. Crossref

  20. Halapi Eva, Oligoclonal T cells in human cancer, Medical Oncology, 15, 4, 1998. Crossref

  21. Li X, Takahashi Y, Sakamoto K, Nakashima T, Expression of dendritic cell phenotypic antigens in cervical lymph nodes of patients with hypopharyngeal and laryngeal carcinoma, The Journal of Laryngology & Otology, 123, S31, 2009. Crossref

  22. Bien Ewa, Balcerska Anna, Adamkiewicz-Drozynska Elzbieta, Rapala Malgorzata, Krawczyk Malgorzata, Stepinski Jan, Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias, Clinical Biochemistry, 42, 10-11, 2009. Crossref

  23. Witz Isaac P., Levy-Nissenbaum Orlev, The tumor microenvironment in the post-PAGET era, Cancer Letters, 242, 1, 2006. Crossref

  24. Kang Shijun, Yang Chunlan, Luo Rongcheng, Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells, Biochemical and Biophysical Research Communications, 372, 4, 2008. Crossref

  25. Zöller Margot, Matzku Siegfried, Cancer Therapy: New Concepts on Active Immunization, Immunobiology, 201, 1, 1999. Crossref

  26. Galizia Gennaro, Orditura Michele, Romano Ciro, Lieto Eva, Castellano Paolo, Pelosio Luigi, Imperatore Vincenzo, Catalano Giuseppe, Pignatelli Carlo, De Vita Ferdinando, Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery, Clinical Immunology, 102, 2, 2002. Crossref

  27. Zöller Margot, Unexpected Induction of Unresponsiveness by Vaccination With Transformed Salmonella Typhimurium, Journal of Immunotherapy, 25, 2, 2002. Crossref

  28. Deepak Praveen, Kumar Sanjay, Acharya Arbind, Overexpression of Interleukin-13 in a Murine T-Cell Lymphoma: A Possible Factor of DL-Induced Immunosuppression and Tumor Progression, Cancer Investigation, 27, 6, 2009. Crossref

  29. thor Straten Per, Kirkin Alexei F., Siim Elsebeth, Dahlström Karin, Drzewiecki Krzysztof T., Seremet Tina, Zeuthen Jesper, Becker Jürgen C., Guldberg Per, Tumor Infiltrating Lymphocytes in Melanoma Comprise High Numbers of T-Cell Clonotypes That Are Lost during in Vitro Culture, Clinical Immunology, 96, 2, 2000. Crossref

  30. Bhattacharyya Arindam, Mandal Debaprasad, Lahiry Lakshmishri, Sa Gaurisankar, Das Tanya, Black tea protects immunocytes from tumor-induced apoptosis by changing Bcl-2/Bax ratio, Cancer Letters, 209, 2, 2004. Crossref

  31. Matar Pablo, Rozados Viviana R, Gervasoni Silvia I, Scharovsky O.Graciela, Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response, International Immunopharmacology, 1, 2, 2001. Crossref

  32. Liljefors Maria, Nilsson Bo, Hjelm Skog Anna-Lena, Ragnhammar Peter, Mellstedt Håkan, Frödin Jan-Erik, Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A, International Journal of Cancer, 105, 5, 2003. Crossref

  33. De Vita Ferdinando, Orditura Michele, Galizia Gennaro, Romano Ciro, Roscigno Annarita, Lieto Eva, Catalano Giuseppe, Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients, Chest, 117, 2, 2000. Crossref

  34. Sørensen Rikke Bæk, Berge-Hansen Linda, Junker Niels, Hansen Christina Aaen, Hadrup Sine Reker, Schumacher Ton N. M., Svane Inge Marie, Becker Jürgen C., Straten Per thor, Andersen Mads Hald, Unutmaz Derya, The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase, PLoS ONE, 4, 9, 2009. Crossref

  35. Zöller Margot, Immunotherapy of Cancer by Active Vaccination: Does Allogeneic Bone Marrow Transplantation after Non-Myeloablative Conditioning Provide a New Option?, Technology in Cancer Research & Treatment, 2, 3, 2003. Crossref

  36. Kallfelz Michael, Jung Dirk, Hilmes Christine, Knuth Alexander, Jaeger Elke, Huber Christoph, Seliger Barbara, Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer, International Journal of Cancer, 81, 1, 1999. Crossref

  37. Céfai D, Schwaninger R, Balli M, Brunner T, Gimmi C D, Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy, Cell Death & Differentiation, 8, 7, 2001. Crossref

  38. Simonetti O., Goteri G., Lucarini G., Rubini C., Stramazzotti D., Muzio L. Lo, Biagini G., Offidani A., In Melanoma Changes of Immature and Mature Dendritic Cell Expression Correlate with Tumor Thickness: An Immunohistochemical Study, International Journal of Immunopathology and Pharmacology, 20, 2, 2007. Crossref

  39. Gritzapis A D, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez S A, Baxevanis C N, Papamichail M, Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells, British Journal of Cancer, 88, 8, 2003. Crossref

  40. Yoon Do-Young, Cho Young-Sik, Park Joo-Won, Kim Soo-Hyun, Kim Jong-Wan, Up-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor, Clinical Chemistry and Laboratory Medicine (CCLM), 42, 5, 2004. Crossref

  41. Gilboa Eli, The promise of cancer vaccines, Nature Reviews Cancer, 4, 5, 2004. Crossref

  42. Mukherjee Pinku, Ginardi Amelia R., Madsen Cathy S., Sterner Christopher J., Adriance Melissa C., Tevethia Mary J., Gendler Sandra J., Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred, The Journal of Immunology, 165, 6, 2000. Crossref

  43. Walden Peter, Interrelationship of Tumour and Immune System, in Function and Regulation of Cellular Systems, 2004. Crossref

  44. Saio Masanao, Radoja Sasa, Marino Mike, Frey Alan B., Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide, The Journal of Immunology, 167, 10, 2001. Crossref

  45. Radoja Sasa, Rao T. Dharma, Hillman Deborah, Frey Alan B., Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo, The Journal of Immunology, 164, 5, 2000. Crossref

  46. Bell Diana, Chomarat Pascale, Broyles Denise, Netto George, Harb Ghada Moumneh, Lebecque Serge, Valladeau Jenny, Davoust Jean, Palucka Karolina A., Banchereau Jacques, In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas, Journal of Experimental Medicine, 190, 10, 1999. Crossref

  47. Sleeman J. P., The Lymph Node as a Bridgehead in the Metastatic Dissemination of Tumors, in Lymphatic Metastasis and Sentinel Lymphonodectomy, 157, 2000. Crossref

  48. Zbar Andrew P., Tumor Immunobiology, in Immunology for Surgeons, 2002. Crossref

  49. Ohm Joyce E., Gabrilovich Dmitry I., Sempowski Gregory D., Kisseleva Ekaterina, Parman Kelly S., Nadaf Sorena, Carbone David P., VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression, Blood, 101, 12, 2003. Crossref

  50. Andersen Mads Hald, Becker Jürgen C., Straten Per thor, Regulators of apoptosis: suitable targets for immune therapy of cancer, Nature Reviews Drug Discovery, 4, 5, 2005. Crossref

  51. Sredni Benjamin, Weil Merav, Khomenok Gennadi, Lebenthal Ilana, Teitz Seagal, Mardor Yael, Ram Zvi, Orenstein Arie, Kershenovich Amir, Michowiz Shalom, Cohen Yan I., Rappaport Zvi H., Freidkin Ilya, Albeck Michael, Longo Dan L., Kalechman Yona, Ammonium Trichloro(dioxoethylene- o,o ′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop, Cancer Research, 64, 5, 2004. Crossref

  52. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA, Young MD, Holt JK, Trown P, Hermiston TW, Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region, Gene Therapy, 8, 15, 2001. Crossref

  53. Chen C, Fang H, Han Z, Ye F, Ji T, Gong D, Li F, Zhou J, Ma D, Gao Q, Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs, Gene Therapy, 21, 11, 2014. Crossref

  54. Al-Waili Noori S., Saloom Khelod Y., Al-Waili Thia, Al-Waili Ali, Al-Waili Hamza, Modulation of prostaglandin activity, part 1: Prostaglandin inhibition in the management of nonrheumatologic diseases: Immunologic and hematologic aspects, Advances in Therapy, 24, 1, 2007. Crossref

  55. Cui Jiuwei, Li Lingyu, Wang Chang, Jin Haofan, Yao Cheng, Wang Yizhuo, Li Dan, Tian Huimin, Niu Chao, Wang Guanjun, Han Wei, Xu Jianting, Chen Jingtao, Li Wei, Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma, Cytotherapy, 17, 7, 2015. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain